Cardiovascular safety of oncologic agents: double-edged sword even in the era of targeted therapies - Part 1.

Cardiovascular safety of oncologic agents: double-edged sword even in the era of targeted therapies - Part 1. Expert Opin Drug Saf. 2018 Aug 20;: Authors: Manolis AA, Manolis TA, Mikhailidis DP, Manolis AS Abstract INTRODUCTION: Cancer patients are subject to cardiotoxic effects of cancer therapy and as more patients survive cancer due to improved treatment they are exposed to various forms of cardiovascular (CV) disease (CVD) as they age, and vice-versa. Such an interplay of age with both malignancy and CVD may contribute to increased morbidity and mortality. Areas covered: This review considers the effects of cancer drug treatment on the CV system. In Part I of this review, the various types of CV and cardiometabolic toxicity of anti-cancer drugs and the possible mechanisms involved are discussed. Also, among the specific oncologic agents, the CV effects of the classical agents and of the large molecule immunological agents (monoclonal antibodies, including immune check-point inhibitors) are detailed. Expert opinion: Oncologic agents produce a variety of CV adverse effects, including cardiomyopathy and heart failure, peri-myocarditis, coronary artery disease, peripheral vascular disease, hypertension, cardiac arrhythmias, valvular heart disease and pulmonary hypertension. Both the oncologist and the cardiologist need to be aware of such adverse effects and of the specific agents that they produce them and join forces in preventing,...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research